BioNTech Expect to Authorize a Share Repurchase Program of up to $1.5 Billion Over the Next Two Years

BioNTech announces Fourth Quarter And Full Year 2021 Financial Results And Corporate Update.

• Fourth quarter and full year revenues of €5.5 billion1and €19.0 billion1, respectively
• Full year net income of €10.3 billion and fully diluted earnings per share of €39.63 ($46.872)
• Expect to authorize a share repurchase program of up to $1.5 billion over the next two years and will propose a special cash dividend of €2.00 per share, pending approval at the Annual General Meeting
• Approximately 2.6 billion doses of COMIRNATY®/BNT162b2 delivered to more than 165 countries and regions worldwide in 2021, including more than 1 billion doses to low- and middle-income countries
• Reiterate BioNTechCOVID-19 2022 vaccine revenue guidance of €13 billion to €17 billion
• Signed orders for 2022 delivery increased to 2.4 billion COVID-19 vaccine doses
• Expanded clinical stage oncology pipeline to 16 clinical programs with initiation of nine clinical trials, including four randomized Phase 2 trials
• Initiated expansion of Phase 3 clinical trials to include Omicron-based vaccine candidates, and expanded mRNA vaccine pipeline with multiple preclinical programs addressing high-need infectious diseases expected to advance into the clinic this year
• Focused on driving further transformation in 2022 by reinvesting COVID-19 vaccine profits to accelerate oncology and infectious disease programs, broaden pipeline and scale-up business

BioNTech shares gained more than 2% in premarket trading.